FLXN
FLXN Real Time Price USDRecent trades of FLXN by members of U.S. Congress
|
Name
|
Type
|
Shares
|
Price
|
Shares Held
|
Date
|
Reported
|
|---|
|
Investor
|
Shares
|
Change in Shares
|
Market Value
|
Date
|
Reported
|
|---|
|
Investor
|
Type
|
Shares
|
Change in Shares
|
Market Value
|
Date
|
Reported
|
|---|
Recently reported changes by institutional investors
Quarterly net insider trading by FLXN's directors and management
Government lobbying spending instances
-
$40,000 Jan 19, 2021 Issue: Health Issues Pharmacy
-
$60,000 Apr 22, 2019 Issue: Health Issues
-
$20,000 Apr 22, 2019 Issue: Health Issues Pharmacy
-
$60,000 Jan 22, 2019 Issue: Health Issues
-
$20,000 Jan 16, 2019 Issue: Health Issues Pharmacy
-
$60,000 Jul 20, 2018 Issue: Health Issues
-
$20,000 Jul 16, 2018 Issue: Pharmacy Health Issues
-
$60,000 Apr 20, 2018 Issue: Health Issues
-
$20,000 Apr 17, 2018 Issue: Pharmacy Health Issues
-
$60,000 Jan 22, 2018 Issue: Health Issues
-
$20,000 Oct 21, 2017 Issue: Health Issues
-
$30,000 Apr 20, 2012 Issue: Medical/Disease Research/Clinical Labs
-
$30,000 Jan 20, 2012 Issue: Medical/Disease Research/Clinical Labs
-
$30,000 Jan 13, 2012 Issue: Medical/Disease Research/Clinical Labs
Estimated quarterly lobbying spending
New patents grants
Federal grants, loans, and purchases
Estimated quarterly amount awarded from public contracts
Number of mentions of FLXN in WallStreetBets Daily Discussion
Recent insights relating to FLXN
Recent picks made for FLXN stock on CNBC
ETFs with the largest estimated holdings in FLXN
The Quiver Smart Score combines our data on Congress Trading, Lobbying, Insider Trading, CNBC Mentions and more to provide a comprehensive view of the strength of a stock's underlying data.
The Smart Score grades stocks on a scale of 1 (weakest) to 10 (strongest) based on the strength of the underlying data.Sign Up to view FLXN Smart Score
See concise summaries of analyst reports, presenting both bullish and bearish arguments for a stock.
Example:
The Bulls Say summary highlights positive aspects of the stock.
The Bears Say summary points out potential risks and negative aspects of the stock.